Tabriz University of Medical Sciences About    Newsletter    Contact Us    Create Account    Log in  

ISSN: 1735-403X      eISSN: 2383-2886  
Services
Export citation
EndNote
Reference Manager
BibTeX
Medlars
Refworks
Mendeley

Cite by
Google Scholar



Article History
Submitted: 07 May 2017
Revised: 13 Nov 2017
Accepted: 14 Nov 2017
First published online: 15 Mar 2018

Article Access Statistics
Abstract Page Views: 26
PDF Downloads: 113
Full Text Views: 0

Pharm Sci. 2018;24(1):44-51 doi: 10.15171/PS.2018.08

Formulation and Design of Probiotic Supplements for Rheumatoid Arthritis Patients

Research Article

Elnaz Vaghef-Mehrabani 1, Aziz Homayouni-Rad 2, Beitullah Alipour 3, Leila Vaghef-Mehrabany 4, Maryam Saghafi-Asl 5 *

1 Students Research Committee, Department of Biochemistry and Diet Therapy, School of Nutrition & Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
2 Department of Food Science and Technology, School of Nutrition & Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
3 Department of Nutrition in Community, School of Nutrition & Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
4 Department of Nutrition, School of Nutrition and Diet Therapy, Tehran University of Medical Sciences, Tehran, Iran.
5 Department of Biochemistry and Diet Therapy, School of Nutrition & Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.



Abstract
Background: Probiotics are live microorganisms with immune-regulatory properties and may be useful for patients suffering from rheumatoid arthritis (RA), an autoimmune inflammatory disorder. The aim of the present study was to formulate L. casei 01 capsules at laboratory scale, and evaluate its effects on the proportion of T-helper type 2 (Th2) anti-inflammatory cytokines to T-helper type 1 (Th1) pro-inflammatory cytokines (Th2/Th1), in RA patients. Methods: After blending the probiotic and excipient (maltodextrin) based on the relevant calculations, the content uniformity of the mixture was evaluated. Furthermore, viability of the probiotic bacteria was assessed during capsules production and throughout three months of storage. In a randomized double-blind placebo-controlled trial, 46 RA patients were supplemented with either the capsules (containing at least 108 CFU of Lactobacillus. casei 01) or placebo (maltodextrin), for eight weeks; DAS28 (Disease activity score 28) as well as serum inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-10 and IL-12) were measured at baseline and the end of study. IL-10/IL-1β, IL-10/IL-6, IL-10/IL-12, IL10/TNF-α and IL-10/(IL-1β+ IL-6+ IL-12+ TNF-α) were calculated, the latter being expressed as IL-10/total Th1, and compared for the groups. Paired samples t test, Wilcoxon signed-rank test and ANCOVA tests were applied. Results: Probiotic powder had been uniformly mixed with the excipient and the bacteria had acceptable viability throughout the study course. Supplementation of RA patients with the capsules resulted in a significant decrease in disease activity (DAS28, P=0.039) and increase in IL-10/TNF-α, IL-10/IL-12 and IL-10/total Th1 (P=0.039, P=0.012 and P=0.014, respectively). At the end of the study, there was a significant difference between the two groups in terms of IL-10/IL-12 and IL-10/total Th1 (P= 0.038 and P= 0.006, respectively). Conclusion: L. casei 01 supplements may have the expected desired anti-inflammatory effects in RA patients. Further clinical trials are warranted to confirm these results.





Comments
First name  
Last name  
Email address  
Comments  
Security code



This Article
PDF

Google Scholar
Articles by Vaghef-Mehrabani E
Articles by Homayouni-Rad A
Articles by Alipour B
Articles by Vaghef-Mehrabany L
Articles by Saghafi-Asl M

PubMed
Articles by Vaghef-Mehrabani E
Articles by Homayouni-Rad A
Articles by Alipour B
Articles by Vaghef-Mehrabany L
Articles by Saghafi-Asl M



Share this article!
© 2016 Tabriz University of Medical Sciences; unless otherwise stated
Press Manuscript Online. Powered by MAADRAYAN